Lv51
1440 积分 2023-05-11 加入
PILRα on tumor cells interacts with the T cell surface protein CD99 to suppress antitumor immunity
9小时前
已完结
DB-1303, a HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising safety profile and anti-tumor efficacy with differentiation from DS-8201a
23天前
已完结
A decade of the Oesophageal Cancer Clinical and Molecular Stratification Consortium
25天前
已完结
The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer
28天前
已完结
Immunogenicity risk assessment and mitigation for engineered antibody and protein therapeutics
1个月前
已完结
STEAP1 protein overexpression is an independent marker for biochemical recurrence in prostate carcinoma
1个月前
已完结
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study
1个月前
已完结
The Nonclinical Safety Assessment of a Novel Anti-CEACAM5 Antibody Exatecan Conjugate Predicts a Low Risk for Interstitial Lung Disease (ILD) in Patients—The Putative Mechanism Behind ILD
1个月前
已完结
IL-2Rα-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25+CD8+ T cells
1个月前
已完结
A phase 1b study of cofetuzumab pelidotin monotherapy in patients with PTK7-expressing recurrent non-small cell lung cancer
1个月前
已完结
皖公网安备34019202002308
